NASDAQ:ARTV Artiva Biotherapeutics (ARTV) Stock Price, News & Analysis $11.91 +0.13 (+1.11%) As of 10:43 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Artiva Biotherapeutics Stock (NASDAQ:ARTV) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Artiva Biotherapeutics alerts:Sign Up Key Stats Today's Range$11.60▼$12.0950-Day Range$6.80▼$11.7852-Week Range$2.22▼$14.53Volume48,167 shsAverage Volume386,318 shsMarket Capitalization$294.40 millionP/E RatioN/ADividend YieldN/APrice Target$39.00Consensus RatingModerate Buy Company Overview Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches. Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors. By combining gene-editing technologies with optimized cell expansion processes, the company aims to enhance tumor targeting, persistence and safety profiles. Its platform supports rapid manufacturing and scalable production, potentially enabling broader patient access and faster clinical development timelines. Founded in 2016 and headquartered in Cambridge, Massachusetts, Artiva Biotherapeutics operates in key biopharma hubs across North America and Europe. The company’s management team brings collective expertise in immuno-oncology, cell therapy manufacturing and clinical development, positioning Artiva to advance its candidate programs through pivotal trials and, ultimately, regulatory approval.AI Generated. May Contain Errors. Read More Artiva Biotherapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks51st Percentile Overall ScoreARTV MarketRank™: Artiva Biotherapeutics scored higher than 51% of companies evaluated by MarketBeat, and ranked 590th out of 911 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingModerate Buy Consensus RatingArtiva Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 1 strong buy rating, 4 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialArtiva Biotherapeutics has a consensus price target of $39.00, representing about 231.1% upside from its current price of $11.78.Amount of Analyst CoverageArtiva Biotherapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Artiva Biotherapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Artiva Biotherapeutics are expected to decrease in the coming year, from ($2.60) to ($2.73) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Artiva Biotherapeutics is -3.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Artiva Biotherapeutics is -3.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArtiva Biotherapeutics has a P/B Ratio of 2.63. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.92% of the float of Artiva Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverArtiva Biotherapeutics has a short interest ratio ("days to cover") of 5.13.Change versus previous monthShort interest in Artiva Biotherapeutics has recently increased by 11.47%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArtiva Biotherapeutics does not currently pay a dividend.Dividend GrowthArtiva Biotherapeutics does not have a long track record of dividend growth. News and Social Media2.0 / 5News Sentiment0.25 News SentimentArtiva Biotherapeutics has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Artiva Biotherapeutics this week, compared to 4 articles on an average week.Search InterestOnly 6 people have searched for ARTV on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Company Ownership2.9 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $15,710,145.00 in company stock, which represents 5.3956% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Artiva Biotherapeutics insiders have bought 3,287.40% more of their company's stock than they have sold. Specifically, they have bought $16,188,035.00 in company stock and sold $477,890.00 in company stock.Percentage Held by Insiders1.80% of the stock of Artiva Biotherapeutics is held by insiders.Percentage Held by InstitutionsArtiva Biotherapeutics has minimal institutional ownership at this time.Read more about Artiva Biotherapeutics' insider trading history. Receive ARTV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Artiva Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ARTV Stock News HeadlinesArtiva Biotherapeutics (NASDAQ:ARTV) Upgraded to "Hold" at Wall Street ZenAugust 8, 2026 | americanbankingnews.comArtiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business HighlightsAugust 6, 2026 | finance.yahoo.com7 Bankers Met in Secret (Now We Pay for It)A little-known meeting in 1910 cost the average American family their entire financial freedom. They met in secret, used fake names, and told absolutely no one where they were going. On November 22nd, 1910, seven of America's most powerful bankers gathered on Jekyll Island to design the Federal Reserve. Their goal? To create a system where they control the money supply and you foot the bill. That system has created $38 trillion in debt, destroyed 98% of the dollar's purchasing power, and now they're preparing the final move: Central bank digital currencies (CBDCs). But if you have at least $100,000 saved and you're concerned about what's coming, you need to hear this.August 12 at 1:00 AM | Decentralized Masters (Ad)Ra Capital Management, L.P. Acquires 20,824 Shares of Artiva Biotherapeutics (NASDAQ:ARTV) StockAugust 1, 2026 | insidertrades.comArtiva Biotherapeutics (NASDAQ:ARTV) Director Purchases 41,319 Shares of StockJuly 29, 2026 | insidertrades.comArtiva Biotherapeutics Sets Deadline for 2026 MeetingJuly 22, 2026 | tipranks.comArtiva Biotherapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 17, 2026 | globenewswire.comRa Capital Management, L.P. Buys 6,552 Shares of Artiva Biotherapeutics (NASDAQ:ARTV) StockJuly 15, 2026 | insidertrades.comSee More Headlines ARTV Stock Analysis - Frequently Asked Questions How have ARTV shares performed this year? Artiva Biotherapeutics' stock was trading at $4.29 at the beginning of the year. Since then, ARTV stock has increased by 174.6% and is now trading at $11.78. How were Artiva Biotherapeutics' earnings last quarter? Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) announced its earnings results on Thursday, August, 6th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.63) by $0.00. When did Artiva Biotherapeutics IPO? Artiva Biotherapeutics (ARTV) raised $209 million in an initial public offering on Friday, July 19th 2024. The company issued 13,920,000 shares at $14.00-$16.00 per share. Who are Artiva Biotherapeutics' major shareholders? Artiva Biotherapeutics' top institutional shareholders include Blue Owl Capital Holdings LP (3.54%), BlackRock Inc. (2.81%) and State of Wyoming (0.02%). Insiders that own company stock include Ra Capital Management, LP, Corp Gc, Yong-Jun Huh, Global Strategic Fund I Venbio, Fred Aslan, Jennifer Bush, Christopher Horan, Heather Raymon and Subhashis Banerjee. View institutional ownership trends. How do I buy shares of Artiva Biotherapeutics? Shares of ARTV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Artiva Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Artiva Biotherapeutics investors own include AST SpaceMobile (ASTS), Tempus AI (TEM), Delcath Systems (DCTH), Advanced Micro Devices (AMD), AngioDynamics (ANGO), Broadcom (AVGO) and Genius Sports (GENI). Company Calendar Last Earnings8/06/2026Today8/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (12m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 ARTV's financial health is in the Green zone, according to TradeSmith. ARTV has been in this zone for over 12 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ARTV Previous SymbolNASDAQ:ARTV CIK1817241 Webwww.artivabio.com Phone(858) 267-4467FaxN/AEmployees81Year Founded2019Price Target and Rating Average Price Target for Artiva Biotherapeutics$39.00 High Price Target$41.00 Low Price Target$35.00 Potential Upside/Downside+228.8%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($3.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$83.86 million Net MarginsN/A Pretax MarginN/A Return on Equity-83.31% Return on Assets-70.63% Debt Debt-to-Equity RatioN/A Current Ratio8.16 Quick Ratio8.16 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.48 per share Price / Book2.65Miscellaneous Outstanding Shares24,717,000Free Float24,272,000Market Cap$293.14 million OptionableN/A Beta2.16 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:ARTV) was last updated on 8/12/2026 by MarketBeat.com Staff. From Our PartnersHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredOne trade you can make to move the needle todayEric Fry has been analyzing markets since the 1980s, working as a professional portfolio manager for over a de...InvestorPlace | SponsoredThe trading strategy that works BECAUSE you have a lifeTim Sykes built a trading strategy for people who can't watch charts from 9:30 to 4:00 every day. It's not ...Tim Sykes | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredA weekly dividend fund holding Nvidia and PalantirCrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...Investors Alley | SponsoredElon's Terrifying Warning: America Is "1,000% Going Bankrupt"The national debt just crossed $39 trillion, and Elon Musk - former head of the Department of Government Effic...American Hartford Gold | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artiva Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Artiva Biotherapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
